Mylan is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company operates in two segments: Generics and Specialty. It manufactures and sells a portfolio of injectable products across various therapeutic areas. The Company markets its products to wholesalers, distributors, retail pharmacy chains, group purchasing organizations, government entities, independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers.

Type
Public
HQ
Canonsburg, US
Founded
1961
Size (employees)
35,000 (est)
Website
mylan.com
Mylan was founded in 1961 and is headquartered in Canonsburg, US
Report incorrect company information

Key People/Management at Mylan

Heather Bresch

Heather Bresch

CEO
Robert Coury

Robert Coury

Non-Executive Director
Wendy Cameron

Wendy Cameron

Non-Executive Director
Robert Cindrich

Robert Cindrich

Non-Executive Director
JoEllen Lyons Dillon

JoEllen Lyons Dillon

Executive Vice-President, Chief Legal Officer

Mylan Office Locations

Mylan has offices in Hertfordshire and Canonsburg
Canonsburg, US (HQ)
1000 Mylan Boulevard
Hertfordshire, GB
Building 4 Trident Place Mosquito Way
Show all (2)
Report incorrect company information

Mylan Financials and Metrics

Mylan Financials

Mylan's revenue was reported to be $7.65 b in FY, 2014 which is a 11.5% increase from the previous period.
USD

Revenue (FY, 2014)

7.6 b

Revenue growth (FY, 2013 - FY, 2014), %

11.5%

Gross profit (FY, 2014)

3.5 b

Gross profit margin (FY, 2014), %

45.2%

Net income (FY, 2014)

933.1 m

Market capitalization (14-Jun-2018)

20.4 b

Closing share price (14-Jun-2018)

39.5

Cash (31-May-2017)

24.2 k
Mylan's current market capitalization is $20.4 b.
USDFY, 2013FY, 2014

Revenue

6.9 b7.6 b

Revenue growth, %

12%

Cost of goods sold

3.9 b4.2 b

Gross profit

3 b3.5 b
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

2.5 k5.9 k1.8 k163 32 5.1 k5.2 k28.9 k15.3 k28.7 k24.2 k

Accounts Receivable

975 372 2.5 k17.4 k5.4 k5 k9.3 k20 k12.7 k54.9 k

Inventories

1.7 b1.7 b

Current Assets

3.4 k5.9 k2.2 k2.6 k17.4 k10.5 k10.2 k38.1 k35.3 k41.4 k79.1 k
Annual
USDFY, 2013FY, 2014

Net Income

626.5 m933.1 m

Depreciation and Amortization

516 m566.6 m

Inventories

(160 m)(150 m)

Accounts Payable

137.2 m(300 k)
Quarterly
USDQ1, 2018

Long-term Borrowings

(498 m)
Show all financial metrics
Report incorrect company information

Mylan Online and Social Media Presence

Embed Graph
Report incorrect company information

Mylan News and Updates

Mylan scores FDA approval of generic Suboxone for opioid addiction, but a strong launch is no sure bet

Just one day after the FDA warned Mylan it would issue a second thumbs-down on its generic asthma drug Advair, the agency granted the company one of two approvals of the first generic version of sublingual Suboxone. But competition and legal holdups threaten to stifle the launch.

FDA strikes down Mylan's generic Advair—again—citing 'minor' issues

Thought Mylan might snag a generic Advair approval on its second try? Think again. On Wednesday, the company said an FDA rejection for its copy of the GlaxoSmithKline respiratory behemoth was on the way, thanks to “minor deficiencies” in its application. The agency will dig into what those are in a …

UPDATE 2-FDA finds deficiencies in Mylan's generic Advair; shares fall

* Shares fall 4.5 pct after market (Adds analyst comment; updates shares)

UPDATE 1-FDA finds deficiencies in Mylan's generic Advair; shares fall

June 13 (Reuters) - Mylan NV said on Wednesday that U.S. health regulators were unable to approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug Advair, citing "minor deficiencies" with the drug.
Show more
Report incorrect company information